Oncotelic Therapeutics to undergo significant fair-value remeasurement of GMP Bio stake.
ByAinvest
Thursday, Nov 20, 2025 8:37 am ET1min read
IOBT--
Oncotelic Therapeutics Inc. is preparing for a significant fair-value remeasurement of its 45% stake in joint venture GMP Bio, driven by a new independent valuation indicating a potential step-up in asset value. This shift strengthens Oncotelic Therapeutics' position in the oncology space, making it a key player alongside other innovative leaders like IO Biotech Inc. and Novartis AG. The remeasurement under US GAAP will provide a clearer picture of the company's scientific and commercial progress.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet